Company: PCRX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001396814-25-000102
Chunk: 53

Company: Pacira BioSciences, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 53
---
 $7,573 $7,548 Supplemental cash flow information related to operating leases is as follows (in thousands):Six Months EndedJune 30,20252024Cash paid for operating lease liabilities, net of lease incentives$6,458 $6,429 Right-of-use assets recorded in exchange for lease obligations$1,875 $— The Company has elected to net the amortization of the right-of-use asset and the reduction of the lease liability principal in other liabilities in the condensed consolidated statements of cash flows.The Company has measured its operating lease liabilities at an estimated discount rate at which it could borrow on a collateralized basis over the remaining term for each operating lease. The weighted average remaining lease terms and the weighted average discount rates are summarized as follows:June 30,20252024Weighted average remaining lease term4.79 years5.58 yearsWeighted average discount rate6.91 %7.00 %

Pacira BioSciences, Inc.  |  Q2 2025 Form 10-Q  |  Page 17

Maturities of the Company’s operating lease liabilities are as follows (in thousands):YearAggregate MinimumPayments Due2025 (remaining six months)$6,388 202612,789 202712,336 202811,188 202911,076 Thereafter6,384    Total future lease payments60,161    Less: imputed interest(9,250)   Total operating lease liabilities$50,911 

NOTE 8—GOODWILL AND INTANGIBLE ASSETS

GoodwillThe Company’s goodwill arose from the GQ Bio Acquisition in February 2025. The change in the carrying value of the Company’s goodwill is summarized as follows (in thousands):Carrying ValueBalance at December 31, 2023$163,243 Goodwill impairment(163,243)Balance at December 31, 2024— Goodwill arising from the GQ Bio Acquisition18,099 Foreign currency adjustments2,201 Balance at June 30, 2025$20,300 Intangible AssetsIntangible assets, net, consists of the in-process research and development, or IPR&D, from the GQ Bio Acquisition and Flexion Acquisition, developed technology from the Flexion Acquisition and MyoScience Acquisition and customer relationships from the MyoScience Acquisition are summarized as follows (dollar amounts in thousands):June 30, 2025Gross